Enanta Pharmaceuticals, Inc. (ENTA)
NASDAQ: ENTA · Real-Time Price · USD
11.55
-0.63 (-5.17%)
At close: Oct 28, 2026, 4:00 PM EDT
11.70
+0.15 (1.29%)
After-hours: Oct 28, 2026, 7:30 PM EDT
Enanta Pharmaceuticals Employees
Enanta Pharmaceuticals had 120 employees as of September 30, 2025. The number of employees decreased by 11 or 8.40% compared to the previous year. That makes Enanta Pharmaceuticals the 30,277th largest employer in the world and 3,871st in the United States.
Employees
120
Change (1Y)
-11
Growth (1Y)
-8.40%
Revenue / Employee
$543,817
Profits / Employee
-$526,917
Market Cap
336.40M
Employees Chart
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Sep 30, 2025 | 120 | -11 | -8.40% |
| Sep 30, 2024 | 131 | -14 | -9.66% |
| Sep 30, 2023 | 145 | -15 | -9.38% |
| Sep 30, 2022 | 160 | 5 | 3.23% |
| Sep 30, 2021 | 155 | 14 | 9.93% |
| Sep 30, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Arcturus Therapeutics Holdings | 111 |
| Alector | 103 |
| Scribe Therapeutics | 82 |
| Agenus | 81 |
| Atea Pharmaceuticals | 55 |
| Contineum Therapeutics | 51 |
| X4 Pharmaceuticals | 45 |
| vTv Therapeutics | 26 |
ENTA News
- 20 hours ago - Enanta announces retirement of CEO Luly, appoints Kieffer as COO - TheFly
- 20 hours ago - Enanta Pharmaceuticals Announces Planned Retirement of Longstanding Chief Executive Officer Jay R. Luly, Ph.D. - Business Wire
- 2 days ago - Enanta announces first patient dosed in Resolve Phase 2b/3 trial - TheFly
- 2 days ago - Enanta Pharmaceuticals Announces First Patient Dosed in the RESOLVE Phase 2b/3 Study of Zelicapavir, a Potential First-in-Disease Treatment for Respiratory Syncytial Virus (RSV) - Business Wire
- 15 days ago - Enanta Pharmaceuticals to Present Data for Zelicapavir, an Oral, Once-Daily, N-Protein Inhibitor, in Development for the Treatment of Respiratory Syncytial Virus, at IDWeek™ 2026 - Business Wire
- 6 weeks ago - Enanta Pharmaceuticals Transcript: H.C. Wainwright 28th Annual Global Investment Conference - Transcripts
- 6 weeks ago - Enanta Pharmaceuticals Transcript: 2026 Global Healthcare Conference - Transcripts
- 1 month ago - Enanta Pharmaceuticals to Participate in September Investor Conferences - Business Wire